- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06391918
Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors
May 10, 2024 updated by: GenVivo, Inc.
A Phase 1 Study of GEN2 in Adult Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
Protocol GVO-1102 is a phase 1, open label, multi-center study in adult patients with locally advanced or metastatic solid tumors.
This study includes two parts: dose escalation and dose expansion.
In the dose escalation phase, GEN2 will be administered at increasing dose levels via intravenous infusion on Days 1, 3 and 8 every 4 weeks.
Valganciclovir will start dosing on Day 12 and continue for 10 days (through Day 21).
Once a recommended dose has been defined in approximately 40-50 patients, the dose expansion phase will initiate.
Approximately 15 patients per tumor type will be enrolled in the dose expansion phase.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
GEN2 is a non-replicating off-the-shelf gene therapy vector product being developed as a cancer immunotherapy to activate a patient's immune system against their personal cancer antigens (neoantigens).
The vector payload encodes for a suicide gene, an enhanced viral thymidine kinase enzyme (HSV-eTK), which in the presence of a prodrug, valganciclovir, causes the tumor to release patient specific tumor antigens.
These neoantigens in the presence of a human immune modulator cytokine, granulocyte-macrophage colony-stimulating factor (hGM-CSF), results in the generation of immune effector cells.
These effector cells maintain continually amplifying therapeutic immune responses as more tumor cells are killed and release antigen and will potentially kill any new tumor metastases that arise.
Study Type
Interventional
Enrollment (Estimated)
91
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: James Chrisman
- Phone Number: 626-441-6695
- Email: GenVivoClinicalOperations@genvivoinc.com
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope
-
Contact:
- Daneng Li, MD
- Phone Number: 626-471-9200
- Email: clinicaltrialsinfo@coh.org
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- Next Oncology
-
Contact:
- Carrie Friedman, RN, BSN, OCN
- Phone Number: 703-636-1473
- Email: carrie.friedman@usoncology.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adult patients with a locally advanced or metastatic solid tumor that has progressed or was non-responsive to prior therapy
- For the dose expansion phase: Patients with hepatocellular carcinoma: no more than 2 prior systemic regimens for metastatic disease. Patients with breast cancer: no more than 2 prior cytotoxic regimens for metastatic disease (single-agent hormone therapy or hormone-based doublets do not count).
- Measurable disease as determined by response evaluation criteria in solid tumors (RECIST) v1.1.
- At least 18 years of age.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1.
- For patients with HCC: Child-Pugh Class A
- Available archived tumor tissue sample or a lesion that can be safely biopsied if the archived sample is not available.
- Adequate renal, liver and bone marrow function.
- Ability to swallow VGCV tablets.
- Willingness of men and women of child-bearing potential (WCBP) to observe conventional and highly effective birth control for the duration of treatment and for 12 months following the last dose of study treatment. Patients who are pregnant or lactating are excluded.
Exclusion Criteria:
- Investigational agent or anticancer therapy within 28 days or 5 elimination half-lives prior to Cycle 1 Day 1.
- Prior receipt of talimogene laherparepvec (TVEC) or any other oncolytic virus; prior receipt of a live vaccine within 28 days prior to Cycle 1 Day 1.
- Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of enrollment (alopecia and other nonacute toxicities are not exclusionary)
- Washout from prior major surgery and radiotherapy (less than 28 days)
- Symptomatic primary central nervous system (CNS) tumor or metastases; symptomatic leptomeningeal carcinomatosis; untreated spinal cord compression. Patients with CNS lesions may be eligible if CNS lesions are asymptomatic or if neurological symptoms are stable, the patient is not receiving steroids to manage CNS symptoms, and no CNS surgery or radiation has been performed for 28 days (14 days for stereotactic radiation).
- Active uncontrolled systemic bacterial, viral, or fungal infection, which in the opinion of the Investigator makes it undesirable for the patient to participate in the trial
- Clinically significant active malabsorption syndrome or other conditions such as refractory nausea and vomiting, external biliary shunt, or significant bowel resection likely to affect gastrointestinal absorption of valganciclovir
- Known contraindications to the ganciclovir class
- For patients with hepatocellular carcinoma, patients with active hepatitis B are excluded; patients with evidence of prior exposure who have a negative hepatitis surface antigen (HbsAg) and who do not require antiviral therapy are allowed. Patients with hepatitis C are allowed but may not be on antiviral therapy during study participation and for two weeks prior to Cycle 1 Day 1.
- Known HIV positivity
- Current treatment with systemic steroids at or above 10 mg/day of prednisone (or its equivalent). Inhalational and topical steroids are acceptable
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the recommended phase 2 dose (RP2D) of GEN2 by intravenous infusion
Time Frame: First 28 days.
|
The RP2D will be determined by evaluating the number of subjects with treatment related adverse events and Dose Limiting Toxicities
|
First 28 days.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability as assessed by adverse event monitoring
Time Frame: Up to 24 months
|
Adverse events as characterized by type, frequency, severity (graded by NCI CTCAE v 5.0), timing, seriousness and relationship to study therapy
|
Up to 24 months
|
Pharmacokinetics (PK): area under the concentration-time curve from the time of dosing to 48 hours after dosing (AUC48h)
Time Frame: Up to 24 months
|
AUC48h will be recorded from the PK plasma samples collected
|
Up to 24 months
|
PK: Maximum Concentration (Cmax)
Time Frame: Up to 24 months
|
Cmax will be recorded from the PK plasma samples collected.
|
Up to 24 months
|
To assess replication competent retrovirus (RCR) in peripheral blood mononuclear cells (PBMCs)
Time Frame: Up to 36 months
|
Up to 36 months
|
|
To assess vector integration into genomic deoxyribonucleic acid (DNA) of PBMCs
Time Frame: Up to 36 months
|
Up to 36 months
|
|
Overall response rate (ORR) by RECIST 1.1 (Response Evaluation in Solid Tumors Version 1.1) by Investigator Review
Time Frame: Up to 24 months
|
ORR is defined as the proportion of participants whose best overall response with confirmation status is rated as (confirmed or unconfirmed) complete response (CR) or (confirmed or unconfirmed) partial response (PR) based on RECIST v1.1.
|
Up to 24 months
|
Disease control rate including a best overall response of Complete Response (CR), Partial Response (PR) or stable disease (SD)
Time Frame: Up to 24 months
|
DCR is defined as the proportion of participants whose best overall response with confirmation status is rated as (confirmed or unconfirmed) CR, (confirmed or unconfirmed) PR or stable disease (SD) based on RECIST v1.1.
|
Up to 24 months
|
Duration of response (DOR)
Time Frame: Up to 24 months
|
DOR is measured from the day the criteria are first met for time point overall response rated as CR or PR (whichever is first recorded) until the first date of documented radiological disease progression per RECIST v1.1 or death in the absence of progression.
|
Up to 24 months
|
Assess the immunogenicity of GEN2
Time Frame: Up to 24 months
|
Serial blood samples will be screened for anti-vector antibodies (AVAs)
|
Up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 4, 2024
Primary Completion (Estimated)
March 1, 2027
Study Completion (Estimated)
March 1, 2028
Study Registration Dates
First Submitted
April 19, 2024
First Submitted That Met QC Criteria
April 25, 2024
First Posted (Actual)
April 30, 2024
Study Record Updates
Last Update Posted (Actual)
May 14, 2024
Last Update Submitted That Met QC Criteria
May 10, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Protocol GVO-1102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Sharing Time Frame
Within one year of Last Patient off.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor, Adult
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
TOLREMO therapeutics AGRecruitingCancer | Adult Solid Tumor | Advanced Solid Tumor | Adult DiseaseSpain, Switzerland
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Invitae CorporationRecruitingCancer | Solid Tumor | Solid Tumor, AdultUnited States
-
Sairopa B.V.RecruitingMetastatic Solid Tumor | Solid Tumor, Adult | Refractory CancerUnited States, Moldova, Republic of
-
Institut CurieRecruitingChemotherapy Effect | Solid Tumor, Adult | Solid Tumor, ChildhoodFrance
-
New York Stem Cell Foundation Research InstituteStevens Institute of TechnologyRecruiting
Clinical Trials on GEN2 + Valganciclovir
-
Vir Biotechnology, Inc.GlaxoSmithKlineCompletedCovid19United States, Canada, Italy, Korea, Republic of, Spain
-
Abbott Medical DevicesTerminated
-
Coapt, LLCCongressionally Directed Medical Research ProgramsCompletedProsthesis User | Congenital Amputation of Upper Limb | Amputation; Traumatic, LimbUnited States
-
Luis Eduardo Morales BuenrostroCompletedKidney Transplantation | Pharmacokinetics | Cytomegalovirus Infections | Therapeutic EquivalencyMexico
-
Coapt, LLCEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedProsthesis User | Congenital Amputation of Upper Limb | Amputation; Traumatic, LimbUnited States
-
Stanford UniversityCompleted
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Weill Medical College of Cornell University; University of North Carolina, Chapel Hill and other collaboratorsCompletedSarcomaUnited States
-
Rabin Medical CenterCompletedInfection in Solid Organ Transplant RecipientsIsrael
-
University of California, San FranciscoRoche Pharma AGCompletedHIV Infections | Cytomegalovirus InfectionsUnited States
-
Hoffmann-La RocheCompletedCytomegalovirus InfectionsUnited States